These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 781602)
1. [Effect of furosemide, potassium canrenoate and D-L-propranolol on blood pressure in spontaneously hypertensive rat]. Altman J; Gordan P; Grünfeld JP Pathol Biol (Paris); 1976 May; 24(5):337-41. PubMed ID: 781602 [TBL] [Abstract][Full Text] [Related]
2. Possible role of an endogenous opioid in the antihypertensive action of propranolol in spontaneously hypertensive rats. Farsang C; Ramirez-Gonzalez MD; Tchakarov L; Kunos G Acta Physiol Hung; 1983; 62(2):167-75. PubMed ID: 6670566 [TBL] [Abstract][Full Text] [Related]
3. The role of potassium-canrenoate in the 3H-noradrenaline uptake and metabolism of the rat heart. Préda I; Sebeszta M; Antalóczy Z Arzneimittelforschung; 1980; 30(3):436-8. PubMed ID: 7387752 [TBL] [Abstract][Full Text] [Related]
4. [Pharmacological lowering of portal pressure in normal rats and in experimental liver cirrhosis]. Altmann O Gastroenterol J; 1991; 51(3-4):142-8. PubMed ID: 1811660 [TBL] [Abstract][Full Text] [Related]
5. Treatment with the arginase inhibitor N(omega)-hydroxy-nor-L-arginine improves vascular function and lowers blood pressure in adult spontaneously hypertensive rat. Bagnost T; Berthelot A; Bouhaddi M; Laurant P; André C; Guillaume Y; Demougeot C J Hypertens; 2008 Jun; 26(6):1110-8. PubMed ID: 18475148 [TBL] [Abstract][Full Text] [Related]
6. [Clinical study of the efficacy of oral potassium canrenoate and spironolactone in essential arterial hypertension]. Tosti-Croce C; Mantellini R; Fanti P; Sciarra F Minerva Med; 1983 Apr; 74(14-15):791-7. PubMed ID: 6339999 [TBL] [Abstract][Full Text] [Related]
7. Selective stimulation of renal PGE2 by potassium canrenoate in essential hypertension. Castellani S; Scarti L; Masotti G; Del Rosso A; Chen JI; Neri Serneri GG Prog Clin Biol Res; 1989; 301():297-301. PubMed ID: 2678128 [No Abstract] [Full Text] [Related]
8. Attenuation by propranolol of exercise training effects in spontaneously hypertensive rats. Ghaemmaghami F; Gauquelin G; Allevard AM; Desplanches D; Favier R; Augoyard G; Gharib C J Hypertens; 1987 Aug; 5(4):445-9. PubMed ID: 3668246 [TBL] [Abstract][Full Text] [Related]
9. Cardioprotection by beta-blockers: molecular and structural aspects in experimental hypertension. Pauletto P; Vescovo G; Scannapieco G; Pessina AC; Dal Palù C Drugs Exp Clin Res; 1990; 16(3):123-8. PubMed ID: 1974839 [TBL] [Abstract][Full Text] [Related]
10. Paradoxical relationship between the superior cervical ganglia and the antihypertensive action of propranolol in the spontaneous hypertensive rat. Tuttle R; Elias B; McCleary M; Endy T J Pharmacol Exp Ther; 1982 Dec; 223(3):824-33. PubMed ID: 7143243 [TBL] [Abstract][Full Text] [Related]
11. Antioestrogenic action of the aldosterone antagonist canrenoate K in the rat (adenohypophysis, ceruloplasmin). Schreiber V; Pribyl T Physiol Bohemoslov; 1977; 26(5):385-95. PubMed ID: 144921 [TBL] [Abstract][Full Text] [Related]
12. Vascular effects of long-term propranolol administration after chronic nitric oxide blockade. Priviero FB; Teixeira CE; Claudino MA; De Nucci G; Zanesco A; Antunes E Eur J Pharmacol; 2007 Oct; 571(2-3):189-96. PubMed ID: 17610863 [TBL] [Abstract][Full Text] [Related]
13. [Influence of canrenoate potassium (aldactone pro injections) on hemodynamics and myocardial ischemia in experimental myocardial infarct]. Kötter V; Leitner Ev; Arbeiter G; Cordes R; Schröder R Z Kardiol; 1975 Jul; 64(7):672-86. PubMed ID: 1163092 [TBL] [Abstract][Full Text] [Related]
14. Chronic treatment with propranolol enhances the synthesis of prostaglandins E2 and I2 by the aorta of spontaneously hypertensive rats. Nishimiya T; Daniell HB; Webb JG; Oatis J; Walle T; Gaffney TE; Halushka PV J Pharmacol Exp Ther; 1990 Apr; 253(1):207-13. PubMed ID: 2109798 [TBL] [Abstract][Full Text] [Related]
15. Effects of K+-canrenoate on the development of DOCA-salt hypertension. Vargas F; Haro JM; Jodar E; Soler A; Garcia del Rio C J Pharm Pharmacol; 1989 May; 41(5):335-8. PubMed ID: 2569521 [TBL] [Abstract][Full Text] [Related]
16. [Potassium canrenoate and the combination of potassium canrenoate-butizide in the therapy of light to moderate arterial hypertension]. Morabito S; Fabiano M; Puliti M; Palumbo R; Marinelli R; Simonetti BM; Pierucci A Clin Ter; 1992 Jul; 141(7):23-8. PubMed ID: 1505173 [TBL] [Abstract][Full Text] [Related]
17. Hypertensive effects of oral administration of the aqueous extract of Solanum torvum fruits in L-NAME treated rats: evidence from in vivo and in vitro studies. Nguelefack TB; Mekhfi H; Dongmo AB; Dimo T; Watcho P; Zoheir J; Legssyer A; Kamanyi A; Ziyyat A J Ethnopharmacol; 2009 Jul; 124(3):592-9. PubMed ID: 19439171 [TBL] [Abstract][Full Text] [Related]
18. [Effect of furosemide and d-1-propranolol on glomerular filtration and renin secretin in rats]. Bonvalet JP; Menard J J Urol Nephrol (Paris); 1975; 81(4-5):320-5. PubMed ID: 1159891 [No Abstract] [Full Text] [Related]
19. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782 [TBL] [Abstract][Full Text] [Related]
20. [Interference of canrenoate potassium with plasma renin activity. Note I. Effects of canrenoate potassiumon plasma renin activity in patients with essential hypertension]. Consolo F; Ferraù O; Pitrone F; Luzza G; Russo A; Virga T Boll Soc Ital Biol Sper; 1975 Dec; 51(24):1943-9. PubMed ID: 1231877 [No Abstract] [Full Text] [Related] [Next] [New Search]